Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remlifanserin - Acadia Pharmaceuticals

Next Previous
Drug Profile

Remlifanserin - Acadia Pharmaceuticals

Alternative Names: AC P204

Latest Information Update: 05 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antidementias; Antipsychotics; Behavioural disorder therapies
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Lewy body disease; Psychotic disorders

Most Recent Events

  • 26 Dec 2025 Phase-III clinical trials in Lewy body disease (In the elderly, In adults, Treatment experienced) in Serbia, France, Italy, Czech Republic, Bulgaria, USA (PO) (NCT07095465) (CTIS-2025-521711-39-00)
  • 31 Jul 2025 ACADIA Pharmaceuticals plans a phase III trial for Lewy body disease (PO, Capsule) in August 2025 (NCT07095465) (EudraCT2025-521711-39-00)
  • 27 Jul 2025 Efficacy and pharmacokinetics data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top